CONCURRENT RADIATION AND GEMCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS

同步放疗和吉西他滨治疗不可切除的头颈部肿瘤

• 批准号: 6274638
• 负责人: Avraham Eisbruch
• 金额: $ 2.15万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274638
• 关键词: antineoplastics; blood chemistry; clinical research; clinical trial phase I; combination cancer therapy; drug metabolism; drug screening /evaluation; head /neck neoplasm; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy

This is a phase I study seeking the maximally tolerated dose of gemcitabine delivered concurrent with a standard course of radiation for patients with unresectable head and neck tumors. Plasma levels and tumor incorporation of gemcitabine, as well as tumor nucleotide pools will be measured in order to gain a better understanding of the mechanisms by which gemcitabine may enhance radiation antitumoral activity in vivo.

这是一项I期研究，寻求最大耐受剂量的 吉西他滨与标准放疗同时给药， 不能切除的头颈部肿瘤患者。 血浆水平和 吉西他滨的肿瘤掺入以及肿瘤核苷酸库 为了更好地了解 吉西他滨可增强放射抗肿瘤作用的机制 体内活性。